We are a clinical-stage biotechnology company focused on transforming patients’ lives by developing and commercializing treatments for immunological and inflammatory diseases.
Our lead clinical candidate, atacicept, is a novel inhibitor of B cells and plasma cells. We are developing atacicept, which is self-administered subcutaneously once per week, for the treatment of IgA nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis or the need for a kidney transplant.
Currently, there are no approved treatments for IgAN. We are committed to changing that.